<DOC>
	<DOCNO>NCT00003280</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know treatment regimen effective lymphoma . PURPOSE : Randomized phase III trial compare effectiveness different regimen rituximab treat patient follicular mantle cell lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Follicular Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess clinical efficacy consolidation treatment rituximab term response rate patient follicular ( closed accrual 9/18/00 ) mantle cell lymphoma . - Compare event free survival patient induction without consolidation . - Compare tolerability two treatment regimen patient . OUTLINE : This randomize , open label , multicenter study . Patients stratify accord participate center , histology ( follicular ( closed accrual 9/18/00 ) v mantle cell ) , status disease ( de novo v relapse vs resistant ) , response induction ( stable disease vs partial complete response ) , treatment status ( treat vs untreated ) . All patient receive induction therapy consist rituximab IV 3-5 hour week week 1-4 . Patients randomize one two treatment arm . - Arm I : Patients observe . - Arm II : Patients receive rituximab IV 3-5 hour week week 12 , 20 , 28 , 36 . Patients follow weekly first month ; every 8 week next 8 month ; 12 , 18 , 24 month ; annually next 3 year . PROJECTED ACCRUAL : A total 240 patient ( 120 per arm ) accrue study within 3-4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven CD20 positive follicular ( close accrual 9/18/00 ) mantle cell lymphoma Untreated `` de novo '' disease OR Chemotherapy resistant disease OR Relapsing disease Bidimensionally measurable disease No symptomatic CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) No hepatitis B C Renal : Creatinine great 2 time ULN Cardiovascular : Ejection fraction least 50 % Other : Not pregnant nursing Fertile patient must use effective contraception No active opportunistic infection HIV negative No prior malignancy within 5 year except adequately treat carcinoma situ cervix localize nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior antibody base therapy Chemotherapy : At least 4 week since prior chemotherapy ( least 6 week since nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : At least 4 week since prior corticosteroid , unless chronic dose great 20 mg/day nonlymphoma related condition No concurrent corticosteroid Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>